Breaking News

Gamida Cell and Lonza to Manufacture Omidubicel

Strategic manufacturing agreement is signed for the future commercial production of Phase 3 investigational advanced cell therapy

Gamida Cell Ltd., a cellular and immune therapeutics company, and Lonza, have entered into a strategic manufacturing agreement for the future commercial production, after potential FDA approval of omidubicel, Gamida Cell’s investigational advanced cell therapy currently in Phase 3 development, designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant. A Phase 3 study of omidubicel in patients with hematologic malignancies is currently ongoing.   The agree...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters